Valuation: TAUNS Laboratories,Inc.

Market Cap 55.74B 354M 311M 295M 267M 502M 33.99B 505M 3.53B 1.36B 17.35B 1.33B 1.3B P/E 2026 *
10.5x
P/E 2027 * 15.5x
Enterprise Value 63.73B 405M 356M 337M 305M 574M 38.87B 577M 4.03B 1.56B 19.83B 1.52B 1.49B EV / Sales 2026
-
EV / Sales 2027 * 3.35x
Free-Float
31.29%
Yield 2026 *
6.76%
Yield 2027 * 5.36%
1 day-1.15%
1 week-2.09%
Current month+1.98%
1 month+1.98%
3 months+10.02%
6 months+0.19%
Current year+1.38%
1 week 513
Extreme 513
534
1 month 500
Extreme 500
534
Current year 463
Extreme 463
568
1 year 463
Extreme 463
577
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 2014-04-30
Comptroller/Controller/Auditor - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 51 2014-04-30
Director/Board Member 53 2016-03-31
Director/Board Member 43 2020-08-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.15%-2.09%-8.51% - 358M
+0.05%+1.99%+195.40%+489.92% 23.79B
+3.26%+11.88%+655.12%+114.55% 11.17B
+2.57%+10.24%-29.47%-9.98% 10.42B
-0.72%+3.59%+8.77% - 9.04B
0.00%-0.54%+97.08%+43.45% 6.51B
+3.94%+1.14%-27.39%-21.90% 5.59B
+0.61%+1.67%+6.93%-6.20% 4.45B
-4.05%-7.21%+53.55%+58.57% 3.86B
+1.43%+4.95%-13.29%-25.37% 2.86B
Average +0.59%+2.99%+93.82%+80.38% 7.8B
Weighted average by Cap. +0.91%+4.12%+159.05%+191.07%

Financials

2026 2027 *
Net sales 14.76B 93.75M 82.45M 77.97M 70.72M 133M 9B 134M 934M 361M 4.59B 352M 344M 19.25B 122M 108M 102M 92.26M 173M 11.74B 174M 1.22B 470M 5.99B 459M 449M
Net income 5.2B 33.04M 29.06M 27.48M 24.93M 46.81M 3.17B 47.09M 329M 127M 1.62B 124M 121M 3.59B 22.82M 20.07M 18.98M 17.22M 32.34M 2.19B 32.52M 227M 87.78M 1.12B 85.69M 83.84M
Net Debt 7.99B 50.79M 44.67M 42.24M 38.31M 71.95M 4.88B 72.37M 506M 195M 2.49B 191M 187M 8.75B 55.62M 48.92M 46.26M 41.96M 78.79M 5.34B 79.25M 554M 214M 2.72B 209M 204M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
26-09-28 JP¥516.00 -1.15% 120,000
26-09-28 JP¥522.00 -1.14% 141,800
26-09-25 JP¥528.00 +0.19% 226,900
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
522.00JPY
Average target price
430.00JPY
Spread / Average Target
-17.62%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock